Novel Targets in the Treatment of Advanced Melanoma: New First-Line Treatment Options

Abstract

Spanish

French

OBJECTIVE

To discuss the clinical efficacy and safety of ipilimumab, vemurafenib, and investigational agents for the treatment of unresectable stage III and stage IV melanoma and define current strategies of first-line treatment selection.

DATA SOURCES

Literature was accessed through MEDLINE and International Pharmaceutical Abstracts (1970–November 2012) using the terms melanoma, metastatic melanoma, ipilimumab, vemurafenib, dabrafenib, and trametinib. In addition, reference citations from publications identified were reviewed.

STUDY SELECTION AND DATA EXTRACTION

All articles published in English identified from the data sources were evaluated. Studies and abstracts including more than 10 adult patients were included in the review.

DATA SYNTHESIS

Treatment options for unresectable stage III and IV melanoma are poor and have remained largely unchanged for the past 40 years. Two randomized Phase 3 clinical trials have demonstrated a significant survival benefit with the use of ipilimumab compared to a melanoma vaccine (10.1 vs 6.4 months; p = 0.003) and compared to dacarbazine (11.2 months, 95% CI 9.4–13.6 vs 9.1 months, 95% CI 7.8–10.5). Additionally, long-term follow-up has revealed cases of durable responses of greater than 3 years. Response rates of 50% and greater have been described in vemurafenib-treated patients (1 Phase 1, 1 Phase 2, and 1 Phase 3 randomized trial), although duration of response has not been fully determined. Both new agents possess unique toxicity profiles including immune-related adverse events with ipilimumab and secondary cutaneous cancers reported with vemurafenib use.

CONCLUSIONS

Treatment strategies have changed for patients with advanced melanoma with the use of ipilimumab and vemurafenib as first-line agents. Increased clinical experience and further published data with these and investigational agents will guide the development of treatment algorithms outlining optimal drug selection and sequencing as well as improve management of their novel adverse events.

Get full access to this article

View all access options for this article.

References

1. National Cancer Institute. Melanoma of the skin. http://www.cancer.gov/cancertopics/types/melanoma (accessed 2011 Sept 10).

2. National Cancer Institute. SEER Stats Facts sheets: melanoma of the skin. http://seer.cancer.gov/statfacts/html/melan.html#survival (accessed 2012 Oct 26).

3. National Comprehensive Cancer Network. Melanoma patient guidelines 2011. http://www.nccn.com/images/patient-guidelines/pdf/melanoma.pdf (accessed 2011 Sept 10).

4. Luce

, Thurman

, Isaac

, Talley

. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-tiazeno)imidazole-4-carboxaminde (NSC-45388). Cancer Chemother Rep 1970; 54: 119–24.

5. Avril

, Aamdal

, Grob

, Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 118–25.

6. Bedikian

, Millward

, Pehamberger

, Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group. J Clin Oncol 2006; 24: 4738–45.

7. Chapman

, Einhorn

, Meyers

, Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745–51.

8. Middleton

, Grobb

, Aaronson

, Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158–66.

9. Patel

, Suciu

, Mortier

, Extended schedule escalated dose temozolomide vs dacarbazine in stage IV melanoma: final results of the randomized phase III study (EORTC18032). Eur J Cancer 2011; 47: 1476–83. DOI: 10.1016/j.ejca.2011.04.030

10.

10. Atkins

, Lotze

, Dutcher

, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105–16.

11.

11. Ives

, Stowe

, Lorigan

, Wheatley

. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 5: 5426–34.

12.

12. Hodi

, O'Day

, McDermott

, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23. DOI: 10.1056/NEJMoa1003466

13.

13. Chapman

, Hauschild

, Robert

, Improved survival with vemurafenib in melanoma with mutation. N Engl J Med 2011; 364: 2507–16. DOI: 10.1056/NEJMoa1103782

14.

14. Chapman

, Hauschild

, Robert

, Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. Presented at: American Society of Clinical Oncologist Conference; Chicago, IL; June 1–5, 2012

15.

15. Guerry D. The cellular immunobiology of melanoma. In: Miller

, Maloney

, eds. Cutaneous oncology: pathophysiology, diagnosis and management. Malde, MA: Blackwell Science, 1998: 211–7.

16.

16. Sznol

. Betting on immunotherapy for melanoma. Curr Oncol Rep 2009; 11: 397–404.

17.

17. Komenaka

, Hoerig

, Kaufman

. Immunotherapy for melanoma. Clin Dermatol 2004; 22: 251–65.

18.

18. Frankenthaler

, Sullivan

, Wang

, Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma. Melanoma Res 2010; 20: 496–500.

19.

19. Product information. Yervoy (ipilimumab). Princeton, NJ: Bristol-Myers Squibb, March 2011.

20.

20. Tarhini

, Lo

, Minor

. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 2010; 25: 601–13.

21.

21. Kirkwood

, Tarhini

, Panelli

, Next generation of immunotherapy for melanoma. J Clin Oncol 2008; 26: 3445–55.

22.

22. Ledezma

, Binder

, Hamid

. Atypical clinical response patterns to ipilimumab. Clin J Oncol Nurs 2011; 15: 393–403.

23.

23. Andrews

, Holden

. Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res 2012; 4: 299–307. DOI: 10.2147/CMAR.S31873.

24.

24. Robert

, Thomas

, Bondarenko

, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517–26. DOI: 10.1056/NEJMoa1104621

25.

25. Wolchok

, Neyns

, Linette

, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomized, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155–64. DOI: 10.1016/S1470-2045(09)70334-1

26.

26. National Comprehensive Cancer Network. NCCN guidelines version 2.2013 melanoma. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf (accessed 2012 Oct 25).

27.

27. Pennock

, Waterfield

, Wolchok

. Patient Responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol 2012; 35: 606–11.

28.

28. Maker

, Yang

, Sherry

, Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006; 29: 455–63.

29.

29. Farolfi

, Ridolfi

, Guidoboni

, Ipilimumab in advanced melanoma: reports of long-lasting responses. Melanoma Res 2012; 22: 263–70.

30.

30. McKesson Connect and McKesson Plasma and Biologics Electronic Drug Supply System. San Francisco, CA. 2012. www.mckesson.com/en_us/McKesson.com/Our%2BBusinesses/McKesson%2BPlasma%2B and%2BBioLogics.html (accessed 2013 Mar 25).

31.

31. Dibb

, Dilworth

, Mol

. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nature Rev Cancer 2004; 4: 718–27.

32.

32. Davies

, Bignell

, Cox

, Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–54. DOI: 10.1038/nature00766

33.

33. Long

, Menzies

, Nagrial

, Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 10: 1239–46. DOI: 10.1200/JCO.2010.32.4327

34.

34. Product information. Zelboraf (vemurafenib). South San Francisco, CA: Genentech, August 2011.

35.

35. Flaherty

, Puzanov

, Kim

, Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809–19.

36.

36. Ribas

, Kim

, Schuchter

, BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with mutation-positive metastatic melanoma (abstract 8509). J Clin Oncol 29:2011; 29.

37.

37. Roche Trial database. Clinical trial result information. http://www.rochetrials.com/studyResultGet.action?studyResultNumber=NO25026. (accessed 2012 Jul 25).

38.

38. Aplin

, Kaplan

, Shao

. Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol 2011; 131: 1817–20.

39.

39. Smalley

, Sondak

. Melanoma—an unlikely poster child for personalized cancer therapy. N Engl J Med 2010; 363: 876–8.

40.

40. Poulikakos

, Zhang

, Bollag

, Shokate

, Rosen

. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. Nature 2010; 464: 427–30.

41.

41. US Food and Drug Administration. Medical devices. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm268836.htm (accessed 2012 Oct 30).

42.

42. Hauschild

, Grob

, Demidov

, Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF^V600E-mutated melanoma. Presented at: American Society of Clinical Oncologist Conference; Chicago, IL; June 1–5, 2012.

43.

43. Flaherty

, Robert

, Hersey

, Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107–14. DOI: 10.1056/NEJMoa1203421

44.

44. Flaherty

, Infante

, Daud

, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694–703. DOI:10.1056/NEJMoa1210093

45.

45. Ascierto

, Simeone

, Giannarelli

, Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012; 10: 107.